[
  {
    "ts": null,
    "headline": "Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength",
    "summary": "Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength",
    "url": "https://finnhub.io/api/news?id=011763535065f783fef687a8692dfbf572eec9dbbb228d1269ccd1722f941fb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763657204,
      "headline": "Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength",
      "id": 137564277,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=011763535065f783fef687a8692dfbf572eec9dbbb228d1269ccd1722f941fb2"
    }
  },
  {
    "ts": null,
    "headline": "MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC",
    "summary": "Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.",
    "url": "https://finnhub.io/api/news?id=d116ae1c546f05dfb469d62962543f0f359c28358ff1f36aea02087b15a0451b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763650140,
      "headline": "MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC",
      "id": 137563007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.",
      "url": "https://finnhub.io/api/news?id=d116ae1c546f05dfb469d62962543f0f359c28358ff1f36aea02087b15a0451b"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock",
    "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=2530d2d6c217df7651be2ca39a1f4d77dbd94bd71c37a73cc95dddf786108ee9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763647204,
      "headline": "Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock",
      "id": 137556532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=2530d2d6c217df7651be2ca39a1f4d77dbd94bd71c37a73cc95dddf786108ee9"
    }
  },
  {
    "ts": null,
    "headline": "Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs",
    "summary": "Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.",
    "url": "https://finnhub.io/api/news?id=09dd3679f94372a93ef63c361cf96cbacedec8a701425ad6f5636e74b906167f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763640120,
      "headline": "Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs",
      "id": 137556533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.",
      "url": "https://finnhub.io/api/news?id=09dd3679f94372a93ef63c361cf96cbacedec8a701425ad6f5636e74b906167f"
    }
  },
  {
    "ts": null,
    "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
    "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
    "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763637427,
      "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
      "id": 137557117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
      "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets",
    "summary": "Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed interest in how the company is positioned within the sector. See our latest analysis for Gilead Sciences. Gilead Sciences has enjoyed a wave of positive momentum lately, with its latest share price of $128.07 reflecting strong interest. The company’s share price return year-to-date stands at...",
    "url": "https://finnhub.io/api/news?id=910a7c87212c64428c7bdace30b95e33207d160db35c8eff2b8534c103e88851",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763605003,
      "headline": "Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets",
      "id": 137554112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed interest in how the company is positioned within the sector. See our latest analysis for Gilead Sciences. Gilead Sciences has enjoyed a wave of positive momentum lately, with its latest share price of $128.07 reflecting strong interest. The company’s share price return year-to-date stands at...",
      "url": "https://finnhub.io/api/news?id=910a7c87212c64428c7bdace30b95e33207d160db35c8eff2b8534c103e88851"
    }
  }
]